Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Glioblastoma Multiforme Global Market Report 2025
Download Free Sample Buy Now
Global Glioblastoma Multiforme Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Glioblastoma Multiforme Global Market Report 2025

By Drug Class (Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes), By Diagnostic Tools (Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools), By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types), By End-User (Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Glioblastoma Multiforme Market Overview

• Glioblastoma Multiforme market size has reached to $1.59 billion in 2024

• Expected to grow to $2.27 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%

• Growth Driver: Impact Of Rising Brain Disorder Cases On The Market Growth

• Market Trend: Advancements In CAR T-Cell Therapies For Glioblastoma Multiforme Treatment

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Glioblastoma Multiforme Market?

Glioblastoma multiforme (GBM) is an aggressive and fast-growing brain tumor that originates in the glial cells of the brain. It is the lethal form of primary brain cancer, characterized by rapid proliferation and resistance to standard treatments.

The main types of drug classes for glioblastoma multiforme are chemotherapy agents, temozolomide, carmustine, lomustine, and others. Chemotherapy agents for glioblastoma multiforme target and disrupt cancer cell division, helping control tumor growth and improve survival, often in combination with other treatments. It is diagnosed by various diagnostic tools such as Magnetic Resonance Imaging (MRI), computed tomography scan (CT scan), biopsy, and others and treated with several treatment types, including surgery, radiation therapy, chemotherapy, immunotherapy, tumor treating field therapy, and others. It is used by various end-users, such as hospitals, cancer research institutes, ambulatory surgical centers, and others.

Glioblastoma Multiforme Market Size and growth rate 2025 to 2029: Graph

What Is The Glioblastoma Multiforme Market Size 2025 And Growth Rate?

The glioblastoma multiforme market size has grown strongly in recent years. It will grow from $1.59 billion in 2024 to $1.7 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to the increasing incidence of glioblastoma multiforme, rising healthcare infrastructure, increased awareness, increased access to advanced therapies, and growing aging population.

What Is The Glioblastoma Multiforme Market Growth Forecast?

The glioblastoma multiforme market size is expected to see strong growth in the next few years. It will grow to $2.27 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to an increase in cases of brain and other nervous system cancers, increasing acceptability of surgical techniques, rising awareness, early diagnosis of disease, and an increase in the number of R&D activities. Major trends in the forecast period include advances in medical technology, advancements in imaging techniques, personalized medicine, AI for diagnosis, and technological and scientific developments.

The forecast of 7.5% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. neuro-oncology centers by driving up the cost of tumor-treating fields (TTF) devices and temozolomide sourced from Israel and India, exacerbating treatment delays and elevating brain cancer care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Glioblastoma Multiforme Market Segmented?

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes

2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools

3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types

4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites

2) By Temozolomide: Branded (Temodar), Generic Temozolomide

3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)

4) By Lomustine: Branded (Gleostine), Generic Lomustine

5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

What Is Driving The Glioblastoma Multiforme Market? Impact Of Rising Brain Disorder Cases On The Market Growth

The rising brain disorder cases are expected to drive the glioblastoma multiforme market going forward. A brain disorder is a condition that affects the structure or function of the brain, leading to cognitive, emotional, or physical impairments. Rising brain disorder cases are due to factors such as aging populations, increased life expectancy, lifestyle factors, and improved diagnostic capabilities. Understanding brain disorders helps advance research on glioblastoma multiforme (GBM), leading to better early detection, innovative treatments, and improved patient outcomes. By studying neurological conditions, scientists can uncover genetic and molecular links that contribute to GBM development. For instance, in February 2025, according to Dementia Australia, an Australia-based non-profit organization, approximately 433,300 Australians are living with dementia, with this number expected to rise to 812,500 by 2054. Additionally, younger-onset dementia affects around 29,000 people in 2025, with projections indicating an increase to 41,000 by 2054. Therefore, the rising brain disorder cases will drive the growth of the glioblastoma multiforme industry.

Who Are The Major Players In The Global Glioblastoma Multiforme Market?

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

What Are The Key Trends Of The Global Glioblastoma Multiforme Market? Advancements In CAR T-Cell Therapies For Glioblastoma Multiforme Treatment

Major companies operating in the glioblastoma multiforme market are focusing on developing advanced therapies, such as CAR T-cell therapies, to address the unmet medical needs of aggressive cancer. CAR T-cell therapies are a form of immunotherapy that involves modifying a patient's T-cells to target and kill cancer cells more effectively. For instance, in June 2023, Chimeric Therapeutics Limited, an Australia-based biotech company, launched a Phase IB clinical trial of CHM 1101 (CLXT CAR T) therapy for recurrent or progressive glioblastoma multiforme (GBM). The trial, conducted at multiple centers, aims to evaluate the therapy's safety and efficacy while determining the recommended Phase 2 dose. Initial Phase 1a results showed disease stability, and the trial will build on this to support further development. The company plans to use the data to design a registration trial and seek regulatory feedback.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Glioblastoma Multiforme Market? ITM Isotope Technologies Partnered With Helmholtz Center Munich To Advance Glioblastoma Multiforme Treatment

In January 2022, ITM Isotope Technologies Munich SE (ITM), a Germany-based radiopharmaceutical biotech company, partnered with Helmholtz Center Munich to enhance treatment options for glioblastoma multiforme. This partnership aims to advance the clinical development of a targeted radiopharmaceutical therapy for glioblastoma multiforme, addressing a significant unmet medical need in treating this aggressive cancer. Helmholtz Center Munich is a Germany-based research center focusing on developing immunotherapy for the treatment of glioblastoma.

What Is The Regional Outlook For The Global Glioblastoma Multiforme Market?

North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Glioblastoma Multiforme  Market?

The glioblastoma multiforme market consists of revenues earned by entities by providing services such as palliative care, psychosocial support, and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The glioblastoma multiforme market also includes sales of drugs, diagnostic tools, personalized medicine, and advanced drug delivery systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Glioblastoma Multiforme  Industry?

The glioblastoma multiforme market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glioblastoma multiforme industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Glioblastoma Multiforme Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $1.7 billion
Revenue Forecast In 2034 $2.27 billion
Growth Rate CAGR of 7.5% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The glioblastoma multiforme market covered in this report is segmented –
1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools
3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types
4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users Subsegments:
1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites
2) By Temozolomide: Branded (Temodar), Generic Temozolomide
3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine), Generic Lomustine
5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Glioblastoma Multiforme Market Characteristics

3. Glioblastoma Multiforme Market Trends And Strategies

4. Glioblastoma Multiforme Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Glioblastoma Multiforme Growth Analysis And Strategic Analysis Framework

5.1. Global Glioblastoma Multiforme PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Glioblastoma Multiforme Market Growth Rate Analysis

5.4. Global Glioblastoma Multiforme Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Glioblastoma Multiforme Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Glioblastoma Multiforme Total Addressable Market (TAM)

6. Glioblastoma Multiforme Market Segmentation

6.1. Global Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Chemotherapy Agents

Temozolomide

Carmustine

Lomustine

Other Drug Classes

6.2. Global Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Magnetic Resonance Imaging (MRI)

Computed Tomography Scan (CT Scan)

Biopsy

Other Diagnostic Tools

6.3. Global Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Surgery

Radiation Therapy

Chemotherapy

Immnuotherapy

Tumor Treating Field Therapy

Other Treatment Types

6.4. Global Glioblastoma Multiforme Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Cancer Research Institutes

Ambulatory Surgical Centres

Other End-Users

6.5. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Chemotherapy Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Alkylating Agents

Platinum-Based Agents

Antimetabolites

6.6. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Temozolomide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Branded (Temodar)

Generic Temozolomide

6.7. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Carmustine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Injectable Carmustine

Carmustine Wafers (Gliadel)

6.8. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Lomustine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Branded (Gleostine)

Generic Lomustine

6.9. Global Glioblastoma Multiforme Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Targeted Therapy

Immunotherapy

Tumor-Treating Fields (TTF) Therapy

7. Glioblastoma Multiforme Market Regional And Country Analysis

7.1. Global Glioblastoma Multiforme Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Glioblastoma Multiforme Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Glioblastoma Multiforme Market

8.1. Asia-Pacific Glioblastoma Multiforme Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Glioblastoma Multiforme Market

9.1. China Glioblastoma Multiforme Market Overview

9.2. China Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Glioblastoma Multiforme Market

10.1. India Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Glioblastoma Multiforme Market

11.1. Japan Glioblastoma Multiforme Market Overview

11.2. Japan Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Glioblastoma Multiforme Market

12.1. Australia Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Glioblastoma Multiforme Market

13.1. Indonesia Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Glioblastoma Multiforme Market

14.1. South Korea Glioblastoma Multiforme Market Overview

14.2. South Korea Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Glioblastoma Multiforme Market

15.1. Western Europe Glioblastoma Multiforme Market Overview

15.2. Western Europe Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Glioblastoma Multiforme Market

16.1. UK Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Glioblastoma Multiforme Market

17.1. Germany Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Glioblastoma Multiforme Market

18.1. France Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Glioblastoma Multiforme Market

19.1. Italy Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Glioblastoma Multiforme Market

20.1. Spain Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Glioblastoma Multiforme Market

21.1. Eastern Europe Glioblastoma Multiforme Market Overview

21.2. Eastern Europe Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Glioblastoma Multiforme Market

22.1. Russia Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Glioblastoma Multiforme Market

23.1. North America Glioblastoma Multiforme Market Overview

23.2. North America Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Glioblastoma Multiforme Market

24.1. USA Glioblastoma Multiforme Market Overview

24.2. USA Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Glioblastoma Multiforme Market

25.1. Canada Glioblastoma Multiforme Market Overview

25.2. Canada Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Glioblastoma Multiforme Market

26.1. South America Glioblastoma Multiforme Market Overview

26.2. South America Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Glioblastoma Multiforme Market

27.1. Brazil Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Glioblastoma Multiforme Market

28.1. Middle East Glioblastoma Multiforme Market Overview

28.2. Middle East Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Glioblastoma Multiforme Market

29.1. Africa Glioblastoma Multiforme Market Overview

29.2. Africa Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Glioblastoma Multiforme Market Competitive Landscape And Company Profiles

30.1. Glioblastoma Multiforme Market Competitive Landscape

30.2. Glioblastoma Multiforme Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Glioblastoma Multiforme Market Other Major And Innovative Companies

31.1. Novartis International AG

31.2. Eli Lilly and Company

31.3. Amgen Inc.

31.4. Merck KGaA

31.5. Teva Pharmaceutical Industries Ltd.

31.6. Sun Pharmaceutical Industries Ltd.

31.7. Zydus Pharmaceuticals (USA) Inc.

31.8. Accord Healthcare Inc.

31.9. Sumitomo Dainippon Pharma Oncology Inc.

31.10. Karyopharm Therapeutics Inc.

31.11. ITM Isotope Technologies Munich SE

31.12. Azurity Pharmaceuticals Inc.

31.13. Genenta Science S.p.A.

31.14. Chimeric Therapeutics Limited

31.15. VBI Vaccines Inc.

32. Global Glioblastoma Multiforme Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glioblastoma Multiforme Market

34. Recent Developments In The Glioblastoma Multiforme Market

35. Glioblastoma Multiforme Market High Potential Countries, Segments and Strategies

35.1 Glioblastoma Multiforme Market In 2029 - Countries Offering Most New Opportunities

35.2 Glioblastoma Multiforme Market In 2029 - Segments Offering Most New Opportunities

35.3 Glioblastoma Multiforme Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Glioblastoma Multiforme Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Chemotherapy Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Temozolomide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Carmustine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Lomustine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Glioblastoma Multiforme Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Glioblastoma Multiforme Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Pfizer Inc. Financial Performance
  • Table 81: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 82: AbbVie Inc. Financial Performance
  • Table 83: Bristol Myers Squibb Company Financial Performance
  • Table 84: AstraZeneca PLC Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Glioblastoma Multiforme Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Chemotherapy Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Temozolomide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Carmustine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Lomustine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Glioblastoma Multiforme Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Glioblastoma Multiforme Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Glioblastoma Multiforme Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Glioblastoma Multiforme Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Glioblastoma Multiforme Market, Segmentation By Diagnostic Tools, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Glioblastoma Multiforme Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Pfizer Inc. Financial Performance
  • Figure 81: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 82: AbbVie Inc. Financial Performance
  • Figure 83: Bristol Myers Squibb Company Financial Performance
  • Figure 84: AstraZeneca PLC Financial Performance

Next-Gen Primary Health Care Service : Market Forecast, Transformation, and Long-Term Trajectories

Read More About Next-Gen Primary Health Care Service : Market Forecast, Transformation, and Long-Term Trajectories

Progressive Ataxia And Weakness Disorders Growth Trajectory: Key Forecasts and Strategic Insights

Read More About Progressive Ataxia And Weakness Disorders Growth Trajectory: Key Forecasts and Strategic Insights

Prostate Cancer Nuclear Medicine Diagnostics Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Read More About Prostate Cancer Nuclear Medicine Diagnostics Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Emerging Trends Redefining the Prostate Cancer Nuclear Medicine Diagnostics Market Landscape: Automated Parallel Capillary Electrophoresis Systems Transforming Protein Analysis In The Protein Chip Market

Read More About Emerging Trends Redefining the Prostate Cancer Nuclear Medicine Diagnostics Market Landscape: Automated Parallel Capillary Electrophoresis Systems Transforming Protein Analysis In The Protein Chip Market

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

Read More About A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Read More About A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Read More About A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Read More About Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Glioblastoma Multiforme Global Market Report 2025 – By Drug Class (Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes), By Diagnostic Tools (Magnetic Resonance Imaging (MRI), Computed Tomography...

View Report

Glioblastoma Multiforme (GBM) Treatment Global Market Report 2025 – By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy), By Drug Class (Temozolomid...

View Report

Glioma Treatment Global Market Report 2025 – By Type (Low-Grade, High-Grade), By Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Other Diseases), By Route Of Administration (Oral, ...

View Report

Adult Malignant Glioma Therapeutics Global Market Report 2025 – By Type Of Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types), By Therapy (Ch...

View Report

Paraganglioma Global Market Report 2025 – By Type (Sympathetic Paragangliomas, Parasympathetic Paragangliomas, Caroid Paragangliomas, Cervical Paragangliomas, Jugular Paragangliomas, Secretory Paragangliomas, Temporal Pa...

View Report

Acoustic Neuroma Global Market Report 2025 – By Type (Unilateral Vestibular Schwannomas, Bilateral Vestibular Schwannomas), By Treatment Type (Drugs, Anticonvulsants, Radiation Therapy, Proton Therapy, Stereotactic Radio...

View Report

Pontine Glioma Drugs Global Market Report 2025 – By Type (Diffuse Brain Stem Glioma, Focal Brain Stem Glioma, Recurrent Brain Stem Glioma), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Application (Ca...

View Report

Brain Tumor Drugs Global Market Report 2025 – By Drugs (Temozolomide, Bevacizumab, Other Drugs), By End User (Hospital Pharmacies, Retail Pharmacies/Drug Stores, Other End-Users) – Impact of Tariff and Trade War on Marke...

View Report

Frequently Asked Questions

Glioblastoma multiforme (GBM) is an aggressive and fast-growing brain tumor that originates in the glial cells of the brain. It is the lethal form of primary brain cancer, characterized by rapid proliferation and resistance to standard treatments. For further insights on this market, request a sample here

The market major growth driver - Impact Of Rising Brain Disorder Cases On The Market Growth. For further insights on this market, request a sample here

The glioblastoma multiforme market size has grown strongly in recent years. It will grow from $1.59 billion in 2024 to $1.7 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to the increasing incidence of glioblastoma multiforme, rising healthcare infrastructure, increased awareness, increased access to advanced therapies, and growing aging population. The glioblastoma multiforme market size is expected to see strong growth in the next few years. It will grow to " $2.27 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to an increase in cases of brain and other nervous system cancers, increasing acceptability of surgical techniques, rising awareness, early diagnosis of disease, and an increase in the number of R&D activities. Major trends in the forecast period include advances in medical technology, advancements in imaging techniques, personalized medicine, AI for diagnosis, and technological and scientific developments. For further insights on this market, request a sample here

The glioblastoma multiformemarket covered in this report is segmented –
1) By Drug Class: Chemotherapy Agents; Temozolomide; Carmustine; Lomustine; Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI); Computed Tomography Scan (CT Scan); Biopsy; Other Diagnostic Tools
3) By Treatment Type: Surgery; Radiation Therapy; Chemotherapy; Immunotherapy; Tumor Treating Field Therapy; Other Treatment Types
4) By End-User: Hospitals; Cancer Research Institutes; Ambulatory Surgical Centers; Other End-Users Subsegments:
1) By Chemotherapy Agents: Alkylating Agents; Platinum-Based Agents; Antimetabolites
2) By Temozolomide: Branded (Temodar); Generic Temozolomide
3) By Carmustine: Injectable Carmustine; Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine); Generic Lomustine
5) By Other Drug Classes: Targeted Therapy; Immunotherapy; Tumor-Treating Fields (TTF) Therapy For further insights on this market, request a sample here

North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc. . For further insights on this market, request a sample here.

Major trends in this market include Advancements In CAR T-Cell Therapies For Glioblastoma Multiforme Treatment. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Glioblastoma Multiforme Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon